Overview
Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce's highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. A Phase 1 clinical trial, named INNATE, for JTX-8064 as a monotherapy and in combination with JTX-4014, Jounce's internal PD-1 inhibitor, or pembrolizumab is currently enrolling patients with advanced solid tumors. Jounce's most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. JTX-4014 is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce's broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc.
Basic Stats
The share price of Jounce Therapeutics Inc as of May 3, 2023 is $1.88 / share.
The Factor Analysis chart (below right) shows a view of Jounce Therapeutics Inc from a variety of lenses. Each factor shows how well the company ranks against all other companies in the Fintel global investing universe. Factor scores range from zero to 100, with 100 being most desirable, and 50 being average.
For example, a company with a Value Score of 100 would be the most undervalued company in our database. A company with a Value Score of zero would be the most overvalued.
| Market Cap | |
| EV | |
| Shares Out. | |
| Earnings Date | |
| EPS (TTM) | |
| Dividend Yield | |
| Ex-Dividend Date | |
| Borrow Rate | |
| Short Shares Avail. | |
| Short Interest | |
| Short Float | |
| Days to Cover | |
| Risk Free Rate | 4.17 % |
| Price Change (1 yr) | |
| Volatility (1 yr) | |
| Beta | |
| Sharpe Ratio (1 yr) | |
| Sortino Ratio (1 yr) |
| PE Ratio | |
| Price/Book | |
| Price/TBV | |
| Book/Market | |
| EBIT/EV | |
| EBIT(3yr avg)/EV | |
| ROA | |
| ROE | |
| ROIC | |
| CROIC | |
| OCROIC | |
| Implied Volatility | |
| Put/Call OI Ratio |
| Growth | |
| Profitability | |
| Quality Score | |
| Value Score | |
| Momentum Score | |
| Stability (Low Vol) Score | |
| Analyst Sentiment | |
| Fund Sentiment | |
| Insider Sentiment | |
| Officer Sentiment | |
| Dividend Score | |
| QVM Score | |
| Piotroski F-SCORE |
Factor Scores range from 0 to 100, with 100 being most desirable. Larger circles are better. In situations where we have no data (e.g. no insider trades), we plot the score at 50 to avoid penalizing companies. However, a company that does not pay dividends will get a Dividend Score of Zero. Additionally, we inverted volatility to create a "stability" metric which is better when higher.
Price Target
The average one-year price target for Jounce Therapeutics Inc is $1.65. The forecasts range from a low of $1.01 to a high of $2.10. A stock’s price target is the price at which analysts consider it fairly valued with respect to its projected earnings and historical earnings. Analysts typically set price targets that correspond to their buy or sell recommendations.
Update Frequency: Monthly
Stock Upgrades/Downgrades
This card shows analyst upgrades/downgrades for Jounce Therapeutics Inc. An analyst rating is a classification that gives investors a sense of analyst sentiment about the direction and performance of an equity - usually a stock - over a period of time, typically 12 months.
The standard analyst ratings are generally as follows:
- Buy/Overweight/Outperform - Any of these ratings conveys an analyst’s belief that the stock is likely to outperform a market index (e.g. the S&P 500).
- Hold/Equal-Weight/Market Perform - Any of these ratings conveys an analyst’s belief that the stock is likely to perform in line with a market index.
- Sell/Underweight/Underperform - Any of these ratings suggest that an analyst believes the stock is likely to underperform a market index.
When an analyst upgrades a stock, they are signaling that the company’s fundamentals are being undervalued by investors. It could also mean they believe the market is underestimating the company’s potential. The opposite is true when a stock receives a downgrade.
The average rating of each individual analyst’s rating is the consensus rating for a stock. This gives investors a broader sense of the overall sentiment for that stock.
| Date | Analyst | Prior | Latest Recommendation |
Action |
|---|---|---|---|---|
| 2022-11-11 | Raymond James | Strong Buy | Outperform | Downgrade |
| 2022-08-31 | Raymond James | Strong Buy | Maintains | |
| 2022-08-05 | HC Wainwright & Co. | Buy | Maintains | |
| 2022-05-23 | Piper Sandler | Overweight | Maintains | |
| 2022-05-11 | Baird | Outperform | Neutral | Downgrade |
| 2022-05-06 | Raymond James | Outperform | Strong Buy | Upgrade |
| 2022-03-16 | SMBC Nikko | Outperform | Initiate | |
| 2022-02-04 | Cowen & Co. | Market Perform | Outperform | Upgrade |
| 2021-11-05 | Raymond James | Outperform | Maintains | |
| 2021-09-14 | Raymond James | Market Perform | Outperform | Upgrade |
| 2021-03-15 | Piper Sandler | Overweight | Initiate | |
| 2020-11-10 | Roth Capital | Buy | Maintains | |
| 2020-11-03 | Raymond James | Strong Buy | Market Perform | Downgrade |
| 2020-09-02 | HC Wainwright & Co. | Buy | Maintains | |
| 2020-05-07 | H.C. Wainwright | Buy | Maintains | |
| 2020-03-25 | Raymond James | Outperform | Strong Buy | Upgrade |
| 2020-03-02 | H.C. Wainwright | Buy | Reiterate | |
| 2018-11-14 | JP Morgan | Neutral | Underweight | Downgrade |
| 2018-10-23 | Raymond James | Outperform | Outperform | Maintains |
| 2018-08-10 | JP Morgan | Neutral | Neutral | Maintains |
| 2018-06-28 | Raymond James | Outperform | Initiate | |
| 2018-06-05 | Cowen & Co. | Outperform | Market Perform | Downgrade |
| 2018-06-04 | Wells Fargo | Market Perform | Market Perform | Maintains |
| 2018-06-04 | JP Morgan | Overweight | Neutral | Downgrade |
| 2018-06-04 | Baird | Outperform | Outperform | Maintains |
| 2018-05-17 | Wells Fargo | Outperform | Market Perform | Downgrade |
| 2018-04-27 | H.C. Wainwright | Buy | Initiate | |
| 2017-02-21 | JP Morgan | Overweight | Initiate | |
| 2017-02-21 | Cowen & Co. | Outperform | Initiate | |
| 2017-02-21 | Baird | Outperform | Initiate | |
| 2023-02-23 | Raymond James | Outperform | Market Perform | Downgrade |
| 2023-02-24 | SMBC Nikko | Outperform | Neutral | Downgrade |
| 2023-01-03 | Piper Sandler | Overweight | Maintains |
